Pimozide

Pimozide
Clinical data
Trade names	Orap
AHFS/Drugs.com	Monograph
MedlinePlus	a686018
License data	US FDA: Pimozide;
Pregnancy; category	AU: B1;
Routes of; administration	Oral
Drug class	Typical antipsychotic
ATC code	N05AG02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); US: ℞-only;
Pharmacokinetic data
Bioavailability	40-50%
Metabolism	CYP3A4, CYP1A2 and CYP2D6
Elimination half-life	55 hours (adults), 66 hours (children)
Excretion	Urine
Identifiers
	IUPAC name 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one;
CAS Number	2062-78-4 ;
PubChem CID	16362;
IUPHAR/BPS	90;
DrugBank	DB01100 ;
ChemSpider	15520 ;
UNII	1HIZ4DL86F;
KEGG	D00560 ;
ChEBI	CHEBI:8212 ;
ChEMBL	ChEMBL1423 ;
CompTox Dashboard (EPA)	DTXSID8023474 ;
ECHA InfoCard	100.016.520
Chemical and physical data
Formula	C28H29F2N3O
Molar mass	461.557 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC(N4c3ccccc3NC4=O)CC5;
	InChI InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) ; Key:YVUQSNJEYSNKRX-UHFFFAOYSA-N ;
	(verify)

Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.